12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Avidity Biosciences (RNA) led the gainers with a 38.1% increase, while Tharimmune (THAR) saw the largest drop among the losers, falling 69.5%. Other notable movers included Heart Test Laboratories (HSCS), Redhill Biopharma (RDHL), icad (ICAD), and Eiger BioPharmaceuticals (EIGR) with substantial gains, and SenesTech (SNES), CohBar (CWBR), Nexalin Technology (NXL), Better Therapeutics (BTTX), and Altamira Therapeutics (CYTO) with notable losses.
November 28, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tharimmune shares fell 69.5% to $1.07 in the pre-market session.
The dramatic pre-market decline for Tharimmune could reflect negative investor sentiment or adverse developments, likely leading to further short-term price decreases.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Eiger BioPharmaceuticals shares increased by 10.78% to $0.34, with a market cap of $15.0 million.
Eiger BioPharmaceuticals' pre-market stock price increase could indicate investor optimism or good news, potentially leading to more short-term upward movement.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Heart Test Laboratories shares increased by 22.98% to $0.26, with a market cap of $12.8 million.
The pre-market gain for Heart Test Laboratories may suggest favorable news or investor optimism, potentially leading to further short-term price appreciation.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
icad shares rose by 17.51% to $1.61, with a market cap of $42.4 million.
The pre-market rise in icad's stock price suggests that investors may be reacting to favorable news or developments, which could lead to further short-term gains.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Redhill Biopharma shares moved upwards by 17.99% to $1.18, with a market cap of $13.0 million.
The pre-market increase for Redhill Biopharma could be driven by investor confidence or positive company-specific news, which may result in continued short-term price growth.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Avidity Biosciences shares rose 38.1% to $8.51, with a market cap of $630.6 million.
The substantial pre-market gain for Avidity Biosciences suggests positive investor sentiment or reaction to recent company news, which could lead to continued short-term upward price momentum.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100